Prostate cancer survivors Mark V. Williamson and Jim East will celebrate with other men who beat the disease, Nov. 16 at the ...

Scientists uncover a molecular weakness that could transform prostate cancer therapy. An international team of researchers has identified a new weakness in prostate cancer cells that could enhance ...

GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...

Men with suspected prostate cancer will be able to get a diagnosis on the NHS within a day, under “game-changing” new trials.

Former President Joe Biden spoke publicly for the first time since completing a round of radiation therapy for an aggressive ...

Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a Phase 1b clinical study ...

GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia in a ...

The National Institute for Health and Care Excellence (NICE) has recommended darolutamide in combination with androgen ...

An international collaboration of researchers, including Imperial College London and UCLA, has developed a collagen-binding ...

The baffling question: why does prostate cancer relapse quickly in some patients while stabilising in others? Recent ...

Biotech insiders tout antibody-drug conjugates as the next big thing in cancer treatment, with firms urged to pursue global ...

Male breast and prostate cancer need equal awareness. Know symptoms, risks, and why early detection and regular screening are ...